Ionis Pharmaceuticals and Roche reported positive interim Phase 3 results for sefaxersen, which met its primary endpoint by improving proteinuria versus placebo. IgA nephropathy can lead to end-stage kidney disease in up to 50% of patients, and the study will continue measuring kidney function.

Key Highlights

  • Sefaxersen delivered statistically significant and clinically meaningful proteinuria improvement against placebo in the IMAgINATION study.
  • The investigational treatment is a once-monthly subcutaneous injection intended for self-administration.
  • Roche licensed sefaxersen from Ionis and may provide regulatory and sales milestones plus tiered royalties on net sales.

Sefaxersen Meets Primary Endpoint

Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is a major pharmaceuticals company. The study achieved its primary endpoint, with sefaxersen producing statistically significant and clinically meaningful improvement in proteinuria compared with placebo. The result was measured through the 24-hour urine protein-to-creatinine ratio, or UPCR. The treatment is designed as a once-monthly subcutaneous injection that people can administer themselves. Its safety and tolerability profile remained consistent with earlier data, and no new safety signals were identified. The trial is randomized, double-blind and placebo-controlled. It is continuing in blinded form to assess changes in kidney function through estimated glomerular filtration rate. Interim findings are expected to be presented at a medical congress and shared with health authorities. Roche licensed sefaxersen from Ionis for complement-mediated diseases.